Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 9 de 9
Filtrer
Plus de filtres











Gamme d'année
1.
Drug Test Anal ; 2024 Mar 05.
Article de Anglais | MEDLINE | ID: mdl-38440942

RÉSUMÉ

Driving under the influence of cannabis (DUIC) is increasing worldwide, and cannabis is the most prevalent drug after alcohol in impaired driving cases, emphasizing the need for a reliable traffic enforcement strategy. ∆9 -tetrahydrocannabinol (THC) detection in oral fluid has great potential for identifying recent cannabis use; however, additional data are needed on the sensitivities, specificities, and efficiencies of different oral fluid devices for detecting cannabinoids at the roadside by police during routine traffic safety enforcement efforts. At the roadside, 8945 oral fluid THC screening tests were performed with four devices: AquilaScan®, Dräger DrugTest®, WipeAlyser Reader®, and Druglizer®. A total of 530 samples screened positive for THC (5.9%) and were analyzed by liquid chromatography-tandem mass spectrometry at multiple cutoff concentrations (2 ng/mL, 10 ng/mL, and manufacturers' recommended device cutoffs) to investigate device performance. Results varied substantially, with sensitivities of 0%-96.8%, specificities of 89.8%-98.5%, and efficiencies of 84.3%-97.8%. The Dräger DrugTest® outperformed the other devices with a 96.8% sensitivity, 97.1% specificity, and 97.0% efficiency at a 5-ng/mL LC-MS/MS confirmation cutoff. The WipeAlyser Reader® had good performance with a 91.4% sensitivity, 97.2% specificity, and 96.4% efficiency. AquilaScan® and Druglizer® had unacceptable performance for cannabinoid detection, highlighted by sensitivity <13%. The choice of roadside oral fluid testing device must offer good analytical performance for cannabinoids because of its high prevalence of use and impact on road safety.

2.
Braz. J. Anesth. (Impr.) ; 73(6): 810-818, Nov.Dec. 2023. tab, graf
Article de Anglais | LILACS | ID: biblio-1520373

RÉSUMÉ

Abstract Diversion of substances from the care of the intended patient is a significant problem in healthcare. Patients are harmed by the undertreatment of pain and suffering, transmission of disease, as well as the risk associated with impaired vigilance. Healthcare providers may be harmed by the physical and mental impact of their addictions. Healthcare systems are placed in jeopardy by the legal impact associated with illegal routes of drug release including sanction and financial liability and loss of public trust. Healthcare institutions have implemented many measures to reduce diversion from the perioperative area. These efforts include education, medical record surveillance, automated medication dispensing systems, urine drug testing, substance waste management systems, and drug diversion prevention teams. This narrative review evaluates strengths, weaknesses, and effectiveness of these systems and provides recommendations for leaders and care providers.


Sujet(s)
Humains , Troubles liés à une substance/prévention et contrôle , Anesthésiologistes , Douleur , Personnel de santé , Détournement de médicaments sur ordonnance/prévention et contrôle
3.
Braz J Anesthesiol ; 73(6): 810-818, 2023.
Article de Anglais | MEDLINE | ID: mdl-37517585

RÉSUMÉ

Diversion of substances from the care of the intended patient is a significant problem in healthcare. Patients are harmed by the undertreatment of pain and suffering, transmission of disease, as well as the risk associated with impaired vigilance. Healthcare providers may be harmed by the physical and mental impact of their addictions. Healthcare systems are placed in jeopardy by the legal impact associated with illegal routes of drug release including sanction and financial liability and loss of public trust. Healthcare institutions have implemented many measures to reduce diversion from the perioperative area. These efforts include education, medical record surveillance, automated medication dispensing systems, urine drug testing, substance waste management systems, and drug diversion prevention teams. This narrative review evaluates strengths, weaknesses, and effectiveness of these systems and provides recommendations for leaders and care providers.


Sujet(s)
Anesthésiologistes , Troubles liés à une substance , Humains , Détournement de médicaments sur ordonnance/prévention et contrôle , Troubles liés à une substance/prévention et contrôle , Personnel de santé , Douleur
4.
Bioanalysis ; 15(15): 905-914, 2023 Aug.
Article de Anglais | MEDLINE | ID: mdl-37354101

RÉSUMÉ

Background: Workplace drug testing primarily relies on urine analysis, targeting multiple compounds with varying physicochemical characteristics. Biocompatible solid-phase microextraction (BioSPME) is a miniaturized solid-phase extraction technique that enables the simultaneous extraction and preconcentration of analytes directly from the biological matrix. Methods: The BioSPME procedure consisted of the sequential extraction of 50-µl urine samples using LC Tips C18 in basic and acidic pH, followed by desorption with methanol and n-hexane, respectively. The extracts were analyzed by ultra-performance LC-MS/MS. Results: Intra-day precision was 1.2-8.6% and inter-day precision was 1.8-14.2%. Accuracy was 96.8-107.4%. The extraction yields were 62.8-109.4%. The matrix effects were -3.98% to 1%. Conclusion: BioSPME shows promise as an alternative method for preparing urine samples prior to drug measurement by ultra-performance LC-MS/MS.


Sujet(s)
Cocaïne , Dronabinol , Chromatographie en phase liquide/méthodes , Cocaïne/analyse , Analgésiques morphiniques , Spectrométrie de masse en tandem/méthodes , Extraction en phase solide , Amphétamines/analyse , Chromatographie en phase liquide à haute performance/méthodes
5.
Braz J Anesthesiol ; 71(4): 326-332, 2021.
Article de Anglais | MEDLINE | ID: mdl-33845097

RÉSUMÉ

BACKGROUND: The prevalence of Substance Use Disorders (SUD) and acceptance of drug testing among anesthetists in Brazil has not been determined. METHODS: An internet-based survey was performed to investigate the prevalence of SUD among anesthetists in Brazil, to explore the attitudes of anesthetists regarding whether SUD jeopardizes the health of an impaired provider or their patient, and to determine the provider's perspective regarding acceptance and effectiveness of drug testing to reduce SUD. The questionnaire was distributed via social media. REDCap was utilized to capture data. A sample size of 350 to achieve a confidence level of 95% and confidence interval of 5 was estimated. Study report was based on STROBE and CHERRIES statements. RESULTS: The survey was returned from 1,295 individuals. Most individuals knew an anesthesia provider with a SUD (82.07%), while 23% admitted personal use. The most common identified substances of abuse were opioids (67.05%). Very few respondents worked in a setting that performs drug testing (n = 17, 1.33%). Most individuals believed that drug testing could improve personal safety (82.83%) or the safety of patients (85.41%). Individuals with a personal history of SUD were less likely to believe in the effectiveness of drug testing to reduce one's own risk (74.92% vs. 85.18%, p < 0.0001) or improve the safety of patients (76.27% vs. 88.13%, p < 0.001). CONCLUSIONS: SUDs are common among anesthetists in Brazil. Drug testing would be accepted as a viable means to reduce the incidence although a larger study should be performed to investigate the logistical feasibility.


Sujet(s)
Troubles liés à une substance , Anesthésistes , Brésil/épidémiologie , Humains , Prévalence , Troubles liés à une substance/épidémiologie
6.
Handb Exp Pharmacol ; 265: 269-301, 2021.
Article de Anglais | MEDLINE | ID: mdl-32548785

RÉSUMÉ

The landscape of cancer treatment has improved over the past decades, aiming to reduce systemic toxicity and enhance compatibility with the quality of life of the patient. However, at the therapeutic level, metastatic cancer remains hugely challenging, based on the almost inevitable emergence of therapy resistance. A small subpopulation of cells able to survive drug treatment termed the minimal residual disease may either harbor resistance-associated mutations or be phenotypically resistant, allowing them to regrow and become the dominant population in the therapy-resistant tumor. Characterization of the profile of minimal residual disease represents the key to the identification of resistance drivers that underpin cancer evolution. Therapeutic regimens must, therefore, be dynamic and tailored to take into account the emergence of resistance as tumors evolve within a complex microenvironment in vivo. This requires the adoption of new technologies based on the culture of cancer cells in ways that more accurately reflect the intratumor microenvironment, and their analysis using omics and system-based technologies to enable a new era in the diagnostics, classification, and treatment of many cancer types by applying the concept "from the cell plate to the patient." In this chapter, we will present and discuss 3D model building and use, and provide comprehensive information on new genomic techniques that are increasing our understanding of drug action and the emergence of resistance.


Sujet(s)
Antinéoplasiques , Tumeurs , Antinéoplasiques/pharmacologie , Développement de médicament , Humains , Tumeurs/traitement médicamenteux , Qualité de vie , Biologie des systèmes , Microenvironnement tumoral
7.
Anal Bioanal Chem ; 411(16): 3447-3461, 2019 Jun.
Article de Anglais | MEDLINE | ID: mdl-31123783

RÉSUMÉ

This study aimed to determine simultaneously five major street cocaine adulterants (caffeine, lidocaine, phenacetin, diltiazem, and hydroxyzine) in human urine by dispersive liquid-liquid microextraction (DLLME) and high-performance liquid chromatography. The chromatographic separation was obtained in gradient elution mode using methanol:water plus trifluoroacetic acid 0.15% (v/v) (pH = 1.9) at 1 mL min-1 as mobile phase, at 25 °C, detection at 235 nm, and analysis time of 20 min. The effect of major DLLME operating parameters on extraction efficiency was explored using the multifactorial experimental design approach. The optimum extraction condition was set as 4 mL human urine sample alkalized with 0.5 M sodium phosphate buffer (pH 12), NaCl (15%, m/v), 300 µL acetonitrile (dispersive solvent), and 800 µL chloroform (extraction solvent). Linear response (r2 ≥ 0.99) was obtained in the range of 180-1500 ng mL-1 with suitable selectivity, quantification limit (180 ng mL-1), mean recoveries (33.43-76.63%), and showing relative standard deviation and error (within and between-day assays) ≤15%. The analytes were stable after a freeze-thaw cycle and a short-term room temperature stability test. This method was successfully applied in real samples of cocaine users, suggesting that our study may contribute to the appropriate treatment of cocaine dependence or with the cases of cocaine acute intoxication.


Sujet(s)
Chromatographie en phase liquide à haute performance/méthodes , Cocaïne/urine , Substances illicites/urine , Microextraction en phase liquide/méthodes , Caféine/urine , Humains , Hydroxyzine/urine , Lidocaïne/urine , Limite de détection , Phénacétine/urine , Normes de référence , Reproductibilité des résultats
8.
Subst Use Misuse ; 49(9): 1152-5, 2014 Jul.
Article de Anglais | MEDLINE | ID: mdl-24832912

RÉSUMÉ

Brazil will soon host two major sporting events: the 2014 World Cup and the 2016 Summer Olympic Games. Given the importance of antidoping control during these competitions, it is important that the scientific community receive a status update on antidoping control in Brazil. In this brief communication, the authors present the status of antidoping control in Brazil from an historical perspective, both the benefits and difficulties to be faced by antidoping control during these events, and the legacy resulting from the efficacy of the drug testing performed during these competitions.


Sujet(s)
Dopage sportif/histoire , Détection d'abus de substances/histoire , Brésil , Histoire du 20ème siècle , Histoire du 21ème siècle , Humains
9.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;46(7): 634-642, ago. 2013. graf
Article de Anglais | LILACS | ID: lil-682404

RÉSUMÉ

Current therapy for pancreatic cancer is multimodal, involving surgery and chemotherapy. However, development of pancreatic cancer therapies requires a thorough evaluation of drug efficacy in vitro before animal testing and subsequent clinical trials. Compared to two-dimensional culture of cell monolayer, three-dimensional (3-D) models more closely mimic native tissues, since the tumor microenvironment established in 3-D models often plays a significant role in cancer progression and cellular responses to the drugs. Accumulating evidence has highlighted the benefits of 3-D in vitro models of various cancers. In the present study, we have developed a spheroid-based, 3-D culture of pancreatic cancer cell lines MIAPaCa-2 and PANC-1 for pancreatic drug testing, using the acid phosphatase assay. Drug efficacy testing showed that spheroids had much higher drug resistance than monolayers. This model, which is characteristically reproducible and easy and offers rapid handling, is the preferred choice for filling the gap between monolayer cell cultures and in vivo models in the process of drug development and testing for pancreatic cancer.


Sujet(s)
Humains , Acid phosphatase/métabolisme , Tests de criblage d'agents antitumoraux/méthodes , Tumeurs du pancréas/traitement médicamenteux , Sphéroïdes de cellules/effets des médicaments et des substances chimiques , Antimétabolites antinéoplasiques/administration et posologie , Survie cellulaire , Techniques de culture cellulaire/méthodes , Lignée cellulaire tumorale/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale/enzymologie , Désoxycytidine/administration et posologie , Désoxycytidine/analogues et dérivés , Fluorouracil/administration et posologie , Tumeurs du pancréas/enzymologie , Sphéroïdes de cellules/enzymologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE